NextCure Financial Statements From 2010 to 2025

NXTC Stock  USD 0.80  0  0.12%   
NextCure financial statements provide useful quarterly and yearly information to potential NextCure investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on NextCure financial statements helps investors assess NextCure's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting NextCure's valuation are summarized below:
Gross Profit
-54.2 M
Market Capitalization
22.4 M
Enterprise Value Revenue
1.623
Earnings Share
(2.10)
Quarterly Revenue Growth
(1.00)
We have found one hundred twenty available fundamental ratios for NextCure, which can be analyzed and compared to other ratios and to its peers in the industry. Investors should ensure to check all of NextCure's last-minute performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. As of January 30, 2025, Market Cap is expected to decline to about 34.7 M. In addition to that, Enterprise Value is expected to decline to about 27.6 M
Check NextCure financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NextCure's main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Depreciation And Amortization of 3.2 M or Interest Expense of 6.4 M, as well as many indicators such as Price To Sales Ratio of 14.65, Dividend Yield of 0.0 or PTB Ratio of 0.26. NextCure financial statements analysis is a perfect complement when working with NextCure Valuation or Volatility modules.
  
Check out the analysis of NextCure Correlation against competitors.
For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.

NextCure Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets217.6 M147.2 M117.8 M
Slightly volatile
Short and Long Term Debt Total4.4 M7.6 M3.1 M
Slightly volatile
Other Current Liabilities4.2 M4.5 M3.1 M
Slightly volatile
Total Current Liabilities9.6 M7.9 M6.3 M
Slightly volatile
Other Liabilities768.6 K809.1 KM
Pretty Stable
Property Plant And Equipment Net14.7 M15.4 M12.1 M
Slightly volatile
Accounts Payable2.8 M2.7 MM
Slightly volatile
Cash11.2 M11.8 M21.5 M
Pretty Stable
Non Current Assets Total16.8 M17.6 M13.2 M
Slightly volatile
Non Currrent Assets Other2.3 M2.2 M691.7 K
Slightly volatile
Long Term Debt1.6 M2.1 M1.1 M
Slightly volatile
Cash And Short Term Investments196.3 M124.5 M101.8 M
Slightly volatile
Common Stock Total Equity24.4 K32.2 K18.4 K
Slightly volatile
Common Stock Shares Outstanding23 M32 M17 M
Slightly volatile
Long Term Debt Total1.6 M2.1 M1.1 M
Slightly volatile
Liabilities And Stockholders Equity217.6 M147.2 M117.8 M
Slightly volatile
Non Current Liabilities Total5.8 M6.1 M35.1 M
Slightly volatile
Capital Surpluse305.3 M495.4 M181.1 M
Slightly volatile
Other Current AssetsM5.1 M2.2 M
Slightly volatile
Other Stockholder Equity275.2 M505 M158.6 M
Slightly volatile
Total Liabilities11.6 M12.3 M41 M
Slightly volatile
Property Plant And Equipment Gross22.5 M38.7 M17.2 M
Slightly volatile
Short and Long Term Debt1.1 M1.9 M935.8 K
Slightly volatile
Total Current Assets200.8 M129.6 M104.6 M
Slightly volatile
Net Working Capital191.1 M121.7 M98.3 M
Slightly volatile
Short Term DebtM754.4 K718.7 K
Slightly volatile
Common Stock25.3 K32.2 K18.5 K
Slightly volatile
Property Plant Equipment13.8 M13.7 M11.5 M
Slightly volatile
Capital Stock27.5 K32.2 K18.6 K
Slightly volatile
Non Current Liabilities Other1.1 M706.5 KM
Slightly volatile
Net Receivables825 K920 K727.8 K
Slightly volatile

NextCure Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.2 M4.2 MM
Slightly volatile
Selling General Administrative14.9 M22.7 M9.4 M
Slightly volatile
Other Operating Expenses56.6 M77.8 M37.7 M
Slightly volatile
Research Development41.8 M55.1 M28.3 M
Slightly volatile
Total Operating Expenses56.6 M77.8 M37.7 M
Slightly volatile
Reconciled Depreciation3.7 M4.4 M2.2 M
Slightly volatile
Total Other Income Expense Net5.9 M5.7 M1.8 M
Slightly volatile
Interest IncomeM3.4 M3.7 M
Slightly volatile
Non Operating Income Net Other1.9 M1.1 M3.6 M
Slightly volatile
Selling And Marketing Expenses2.9 M3.3 M3.6 M
Slightly volatile

NextCure Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock171 K180 K35.1 M
Very volatile
Stock Based CompensationM9.4 M3.4 M
Slightly volatile
Begin Period Cash Flow30.3 M24 M22.4 M
Slightly volatile
Other Cashflows From Financing Activities131.7 K138.6 K23.5 M
Slightly volatile
Depreciation3.7 M4.2 M2.2 M
Slightly volatile
Capital Expenditures701.1 K738 K5.6 M
Slightly volatile
End Period Cash Flow11.2 M11.8 M22.5 M
Pretty Stable
Change To Netincome11.6 M11 M3.9 M
Slightly volatile
Issuance Of Capital Stock88.1 K92.7 K83.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio14.6515.4292.2933
Slightly volatile
Stock Based Compensation To Revenue0.260.320.3103
Slightly volatile
Capex To Depreciation0.240.267.8539
Slightly volatile
EV To Sales13.2213.9288.9316
Slightly volatile
Payables Turnover1.491.420.7838
Slightly volatile
Sales General And Administrative To Revenue1.250.881.2702
Slightly volatile
Research And Ddevelopement To Revenue4.112.394.2956
Slightly volatile
Capex To Revenue0.460.370.4635
Slightly volatile
Cash Per Share4.254.474.8825
Slightly volatile
Days Payables Outstanding2522653.6 K
Pretty Stable
Net Debt To EBITDA0.120.130.8002
Very volatile
Current Ratio15.4914.7411.6783
Slightly volatile
Graham Number14.6212.9913.7341
Slightly volatile
Capex Per Share0.03220.03390.4957
Slightly volatile
Revenue Per Share0.490.730.5322
Slightly volatile
Interest Debt Per Share0.130.210.1335
Slightly volatile
Debt To Assets0.04870.04640.0406
Pretty Stable
Days Of Payables Outstanding2522653.6 K
Pretty Stable
Ebt Per Ebit1.051.070.9839
Very volatile
Quick Ratio15.514.7411.6837
Slightly volatile
Net Income Per E B T0.740.840.8963
Slightly volatile
Cash Ratio2.082.193.1939
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.21.171.3667
Slightly volatile
Fixed Asset Turnover0.781.270.8101
Slightly volatile
Debt Ratio0.04870.04640.0406
Pretty Stable
Price Sales Ratio14.6515.4292.2933
Slightly volatile
Asset Turnover0.03630.06570.0358
Slightly volatile
Gross Profit Margin0.80.90.9774
Slightly volatile

NextCure Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap34.7 M36.5 M197.7 M
Pretty Stable
Enterprise Value27.6 M29 M178.2 M
Pretty Stable

NextCure Fundamental Market Drivers

Cash And Short Term Investments108.3 M

NextCure Upcoming Events

7th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About NextCure Financial Statements

NextCure stakeholders use historical fundamental indicators, such as NextCure's revenue or net income, to determine how well the company is positioned to perform in the future. Although NextCure investors may analyze each financial statement separately, they are all interrelated. For example, changes in NextCure's assets and liabilities are reflected in the revenues and expenses on NextCure's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in NextCure. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue149.5 K142 K
Cost Of Revenue3.3 M3.7 M
Stock Based Compensation To Revenue 0.32  0.26 
Sales General And Administrative To Revenue 0.88  1.25 
Research And Ddevelopement To Revenue 2.39  4.11 
Capex To Revenue 0.37  0.46 
Revenue Per Share 0.73  0.49 
Ebit Per Revenue(1.66)(1.74)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether NextCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NextCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nextcure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nextcure Stock:
Check out the analysis of NextCure Correlation against competitors.
For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NextCure. If investors know NextCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NextCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.10)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.31)
Return On Equity
(0.55)
The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NextCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if NextCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NextCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.